Insight

Mohammad Jad Moussa: The new EVP ‘fissure’ challenges the dichotomy of cisplatin/platinum fitness

Photo from Mohammad Jad Moussa/X

Mar 7, 2024, 17:22

Mohammad Jad Moussa: The new EVP ‘fissure’ challenges the dichotomy of cisplatin/platinum fitness

Mohammad Jad Moussa, Postdoc Fellow of GU Oncology at MD Anderson Cancer Center, shared on X/Twitter:

“Our Iceberg Model in Imagining the New 1L Treatment Paradigm of metastatic urothelial cancer with Matt Campbell and Omar Alhalabi.

The new EVP ‘fissure’ challenges the dichotomy of cisplatin/platinum fitness. What lurks beneath the surface?
Emerging biomarkers and treatment strategies.”

Mohammad Jad Moussa: The new EVP 'fissure' challenges the dichotomy of cisplatin/platinum fitness

Proceed to the article.
Source: Mohammad Jad Moussa/X

biomarkers cancer cancer treatment Cisplatin GU Oncology Matt Campbell MD Anderson Cancer Center metastatic urothelial cancer Mohammad Jad Moussa Omar Alhalabi OncoDaily Oncology platinum urothelial cancer

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage